Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Despite proven benefits, prophylactic treatment for hemophilia A is hampered by the short half-life of factor VIII. A recombinant factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an ∼ 2-fold longer half-life than rFVIII...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2012-03, Vol.119 (13), p.3024-3030
Hauptverfasser:	Dumont, Jennifer A., Liu, Tongyao, Low, Susan C., Zhang, Xin, Kamphaus, George, Sakorafas, Paul, Fraley, Cara, Drager, Douglas, Reidy, Thomas, McCue, Justin, Franck, Helen W.G., Merricks, Elizabeth P., Nichols, Timothy C., Bitonti, Alan J., Pierce, Glenn F., Jiang, Haiyan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Clinical Trials and Observations Coagulants - pharmacokinetics Coagulants - therapeutic use Disease Models, Animal Dog Diseases - drug therapy Dog Diseases - metabolism Dogs Factor VIII - chemistry Factor VIII - genetics Factor VIII - pharmacokinetics Factor VIII - therapeutic use Half-Life HEK293 Cells Hematologic and hematopoietic diseases Hemophilia A - drug therapy Hemophilia A - metabolism Hemophilia A - pathology Histocompatibility Antigens Class I - chemistry Histocompatibility Antigens Class I - metabolism Histocompatibility Antigens Class I - pharmacology Histocompatibility Antigens Class I - therapeutic use Humans Medical sciences Mice Mice, Inbred C57BL Mice, Knockout Mice, Transgenic Platelet diseases and coagulopathies Receptors, Fc - chemistry Receptors, Fc - metabolism Receptors, Fc - therapeutic use Recombinant Fusion Proteins - pharmacokinetics Recombinant Fusion Proteins - therapeutic use Thrombosis and Hemostasis Whole Blood Coagulation Time
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!